PLK4 and cancer: These observations may become relevant in the context of cancer treatment efficacy and side effects using newly developed inhibitors that interfere with centriole biogenesis or duplication, such as targeting PLK1, PLK4, or Aurora B kinase, or centrosome dynamics by interfering with proteins regulating centrosomal clustering, for instance by targeting HSET/KIFC1 (Kwon et al, 2008; Chavali et al, 2016; Vitre et al, 2020).